Moasser et al. (2007), in their study of EGFR-TKIs in regulation of tumor vascular functions [34], showed that paclitaxel combined with high-dose gefitinib was better than paclitaxel or gefitinib alone as well as paclitaxel combined a regular-dose gefitinib. This evidence concerns the gene EGFR and neoplasm.